Leslie K. Ballas, MD

home / authors / leslie-k-ballas-md

Articles

Site Logo

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma

Karen M. Winkfield, MD, PhD;Ranjana H. Advani, MD;Leslie K. Ballas, MD;Bouthaina S. Dabaja, MD;Sughosh Dhakal, MD;Christopher R. Flowers, MD, MS;Chul Soo Ha, MD;Bradford S. Hoppe, MD, MPH;David B. Mansur, MD;Nancy P. Mendenhall, MD;Monika L. Metzger, MD;John P. Plastaras, MD, PhD;Kenneth B. Roberts, MD;Ronald Shapiro, MD;Sonali M. Smith, MD;Stephanie A. Terezakis, MD;Anas Younes, MD;Louis S. Constine, MD
December 15th 2016

By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Published: April 26th 2025 | Updated: April 29th 2025
Breast Cancer Disparities May Fuel Guideline-Concordant Care Improvements